Clinical trial
Talabostat in Treating Patients With Metastatic Kidney Cancer
NCT00489710 · University of Nebraska, Other · Withdrawn
Key facts
| NCT number | NCT00489710 |
|---|---|
| Title | Talabostat in Treating Patients With Metastatic Kidney Cancer |
| Official title | A Phase II Study of Talabostat in Patients With Metastatic Renal Cell Carcinoma |
| Lead sponsor | University of Nebraska, Other |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Biological, Diagnostic Test, Drug |
| Interventions | talabostat mesylate, enzyme inhibitor therapy, flow cytometry, laboratory biomarker analysis, non-specific immune-modulator therapy |
| Enrollment | 0 |
| Start date | Dec 1, 2006 |
| Primary completion | May 30, 2007 |
| Completion | May 30, 2007 |
| First posted | Jun 21, 2007 |
| Last update posted | Aug 22, 2023 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: